The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease

Jing He Yan, Kenneth Ataga, Sanjeev Kaul, Jeffery S. Olson, Dennis M. Grasela, Samantha Gothelf, Abdulah Kutlar, Eugene Orringer

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

This was an open-label, nonrandomized, 2-center study conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea in adults with sickle cell disease (SCD). Seventeen patients were divided into 5 groups: normal renal function (n = 7), mild renal impairment (n = 2), moderate renal impairment (n = 3), severe renal impairment (n = 2), and end-stage renal disease (ESRD, n = 3). Except for patients with ESRD, all the patients received a 15-mg/kg single oral dose of hydroxyurea. Patients with ESRD received a 15-mg/kg oral dose of hydroxyurea on 2 occasions. Blood and urine samples were collected for the assessment of hydroxyurea pharmacokinetics. The results indicate that the systemic exposure increases and the urinary recovery decreases as the degree of renal insufficiency worsens. On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7.5 mg/kg/day) for SCD patients with CLCR <60 mL/min. This dosing strategy is anticipated to provide a safe dose for SCD patients with renal impairment.

Original languageEnglish (US)
Pages (from-to)434-445
Number of pages12
JournalJournal of Clinical Pharmacology
Volume45
Issue number4
DOIs
StatePublished - Apr 1 2005
Externally publishedYes

Fingerprint

Hydroxyurea
Sickle Cell Anemia
Pharmacokinetics
Kidney
Chronic Kidney Failure
Renal Insufficiency
Urine

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. / Yan, Jing He; Ataga, Kenneth; Kaul, Sanjeev; Olson, Jeffery S.; Grasela, Dennis M.; Gothelf, Samantha; Kutlar, Abdulah; Orringer, Eugene.

In: Journal of Clinical Pharmacology, Vol. 45, No. 4, 01.04.2005, p. 434-445.

Research output: Contribution to journalArticle

Yan, Jing He ; Ataga, Kenneth ; Kaul, Sanjeev ; Olson, Jeffery S. ; Grasela, Dennis M. ; Gothelf, Samantha ; Kutlar, Abdulah ; Orringer, Eugene. / The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease. In: Journal of Clinical Pharmacology. 2005 ; Vol. 45, No. 4. pp. 434-445.
@article{19636cdd3a8c4619b0ac687e75633420,
title = "The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease",
abstract = "This was an open-label, nonrandomized, 2-center study conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea in adults with sickle cell disease (SCD). Seventeen patients were divided into 5 groups: normal renal function (n = 7), mild renal impairment (n = 2), moderate renal impairment (n = 3), severe renal impairment (n = 2), and end-stage renal disease (ESRD, n = 3). Except for patients with ESRD, all the patients received a 15-mg/kg single oral dose of hydroxyurea. Patients with ESRD received a 15-mg/kg oral dose of hydroxyurea on 2 occasions. Blood and urine samples were collected for the assessment of hydroxyurea pharmacokinetics. The results indicate that the systemic exposure increases and the urinary recovery decreases as the degree of renal insufficiency worsens. On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7.5 mg/kg/day) for SCD patients with CLCR <60 mL/min. This dosing strategy is anticipated to provide a safe dose for SCD patients with renal impairment.",
author = "Yan, {Jing He} and Kenneth Ataga and Sanjeev Kaul and Olson, {Jeffery S.} and Grasela, {Dennis M.} and Samantha Gothelf and Abdulah Kutlar and Eugene Orringer",
year = "2005",
month = "4",
day = "1",
doi = "10.1177/0091270004273526",
language = "English (US)",
volume = "45",
pages = "434--445",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - The influence of renal function on hydroxyurea pharmacokinetics in adults with sickle cell disease

AU - Yan, Jing He

AU - Ataga, Kenneth

AU - Kaul, Sanjeev

AU - Olson, Jeffery S.

AU - Grasela, Dennis M.

AU - Gothelf, Samantha

AU - Kutlar, Abdulah

AU - Orringer, Eugene

PY - 2005/4/1

Y1 - 2005/4/1

N2 - This was an open-label, nonrandomized, 2-center study conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea in adults with sickle cell disease (SCD). Seventeen patients were divided into 5 groups: normal renal function (n = 7), mild renal impairment (n = 2), moderate renal impairment (n = 3), severe renal impairment (n = 2), and end-stage renal disease (ESRD, n = 3). Except for patients with ESRD, all the patients received a 15-mg/kg single oral dose of hydroxyurea. Patients with ESRD received a 15-mg/kg oral dose of hydroxyurea on 2 occasions. Blood and urine samples were collected for the assessment of hydroxyurea pharmacokinetics. The results indicate that the systemic exposure increases and the urinary recovery decreases as the degree of renal insufficiency worsens. On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7.5 mg/kg/day) for SCD patients with CLCR <60 mL/min. This dosing strategy is anticipated to provide a safe dose for SCD patients with renal impairment.

AB - This was an open-label, nonrandomized, 2-center study conducted to assess the influence of renal function on the pharmacokinetics of hydroxyurea in adults with sickle cell disease (SCD). Seventeen patients were divided into 5 groups: normal renal function (n = 7), mild renal impairment (n = 2), moderate renal impairment (n = 3), severe renal impairment (n = 2), and end-stage renal disease (ESRD, n = 3). Except for patients with ESRD, all the patients received a 15-mg/kg single oral dose of hydroxyurea. Patients with ESRD received a 15-mg/kg oral dose of hydroxyurea on 2 occasions. Blood and urine samples were collected for the assessment of hydroxyurea pharmacokinetics. The results indicate that the systemic exposure increases and the urinary recovery decreases as the degree of renal insufficiency worsens. On the basis of the exposure and the apparent clearance from the current and 2 historical studies, the authors have proposed an initial dosing regimen of hydroxyurea (7.5 mg/kg/day) for SCD patients with CLCR <60 mL/min. This dosing strategy is anticipated to provide a safe dose for SCD patients with renal impairment.

UR - http://www.scopus.com/inward/record.url?scp=16844362802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844362802&partnerID=8YFLogxK

U2 - 10.1177/0091270004273526

DO - 10.1177/0091270004273526

M3 - Article

VL - 45

SP - 434

EP - 445

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 4

ER -